HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy

被引：49

作者：

Lanoy, Emilie ^{[2
,3
]}

Rosenberg, Philip S.

Fily, Fabien ^{[4
]}

Lascaux, Anne-Sophie ^{[5
]}

Martinez, Valerie ^{[6
]}

Partisani, Maria ^{[7
]}

Poizot-Martin, Isabelle ^{[8
]}

Rouveix, Elisabeth ^{[9
]}

Engels, Eric A.

Costagliola, Dominique ^{[2
,3
,10
]}

Goedert, James J. ^{[1
]}

机构：

[1] NCI, Div Canc Epidemiol & Genet, Infect & Immunoepidemiol Branch, Rockville, MD 20852 USA

[2] INSERM, Paris, France

[3] Univ Paris 06, Paris, France

[4] Ctr Hosp Univ Pontchaillou, Serv Malad Infect & Reanimat Med, Rennes, France

[5] Hop Henri Mondor, Dept Clin Immunol, F-94010 Creteil, France

[6] Hop Antoine Beclere, AP HP, Serv Med Interne, Clamart, France

[7] Hop Univ, Ctr Soins Infect VIH, Strasbourg, France

[8] Hop St Marguerite, Unite Le Ctr Informat & Soins Immunodeficience Hu, Marseille, France

[9] Hop Ambroise Pare, Serv Med 5, Boulogne, France

[10] Grp Hosp Pitie Salpetriere, AP HP, Serv Malad Infect & Trop, F-75634 Paris, France

来源：

BLOOD | 2011年 / 118卷 / 01期

基金：

美国国家卫生研究院;

关键词：

HUMAN-IMMUNODEFICIENCY-VIRUS; RECONSTITUTION INFLAMMATORY SYNDROME; CANCER-RISK; PERIPHERAL-BLOOD; UNITED-STATES; T-CELLS; AIDS; ERA; DISEASE; RESTORATION;

D O I：

10.1182/blood-2011-02-339275

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hodgkin lymphoma (HL) incidence with HIV infection may have increased with the introduction of combination antiretroviral therapy (cART), suggesting that immune reconstitution may contribute to some cases. We evaluated HL risk with cART during the first months of treatment. With 187 HL cases among 64 368 HIV patients in France, relative rates (RRs) and 95% confidence intervals (CIs) of HL were estimated using Poisson models for duration of cART, CD4 count, and HIV load, with and without adjustment for demographic/clinical covariates. HL risk was unrelated to cART use overall, but it was related to time intervals after cART initiation (P = .006). Risk was especially and significantly elevated in months 1-3 on cART (RR 2.95, CI 1.64-5.31), lower in months 4-6 (RR 1.63), and null with longer use (RR 1.00). CD4 count was strongly associated with HL risk (P < 10(-6)), with the highest HL incidence at 50-99 CD4 cells/mm(3). With adjustment for CD4 count and covariates, HL risk was elevated, but not significantly (RR 1.42), in months 1-3 on cART. HIV load had no added effect. HL risk increased significantly soon after cART initiation, which was largely explained by the CD4 count. Further studies of HIV-associated HL are needed. (Blood. 2011;118(1):44-49)

引用

页码：44 / 49

页数：6

共 36 条

[21]

Müller M, 2010, LANCET INFECT DIS, V10, P251, DOI 10.1016/S1473-3099(10)70026-8

[22] Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22 [J].